Show results for
Refine by
Pancreas Cancer Equipment Supplied In Europe
12 equipment items found
by:Debiopharm based inLausanne, SWITZERLAND
Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction of oxaliplatin, the standard of care for colorectal cancer was 5-fluorouracil (5-FU). Combination of oxaliplatin with 5-FU and leucovorin (FOLFOX) ...
Manufactured by:Universal Diagnostics SL based inSeville, SPAIN
We are developing Signal-X, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. ...
Manufactured by:Yourgene Health based inManchester, UNITED KINGDOM
Elucigene DPYD assay is a simple genotyping test that can identify patients with DPD deficiency allowing an alternative treatment to be offered. 5-fluorouracil (5-FU) is a chemotherapy agent used to treat a range of cancers including colorectal, head and neck, breast, pancreatic and stomach cancer. 5-FU is metabolized by the dihydropyrimidine dehydrogenase enzyme (DPD) which is encoded by the ...
Manufactured by:Auris Medical AG based inBasel, SWITZERLAND
The OligoPhore™ / SemaPhore™ technology has been extensively and successfully tested with various siRNA and mRNA sequences in numerous disease models in mice. For the development of our first proprietary drug product, AM-401 (OligoPhore™ siRNA targeting KRAS), we have initiated a program of IND-enabling ...
Manufactured by:OncoQR ML GmbH based inVienna, AUSTRIA
Lead candidate TYG100 (formerly OQR100, out-licensed to TYG oncology Ltd.) is an “Active Checkpoint Control Immunotherapy (ACCI)” for the treatment of gastroenterological cancers such as pancreatic, stomach, colon, and gastro-esophageal cancer. The immunogen of TYG100 contains a small part of G17 (little ...
Manufactured by:Amadix based inValladolid, SPAIN
PancreaDix is an innovative, non-invasive signature in blood for: Confirming a Pancreatic cancer diagnosis. Detecting pre-malignant lesions that will evolve to cancer. Performing a differential diagnosis between Pancreatic cancer and other pathologies such as chronic pancreatitis or neuroendocrine tumors. ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our medical objective is to validate and bring to clinical use, a novel approach to improve the treatment of metastatic pancreatic adenocarcinoma using a proangiogenic molecule S1P lyase inhibitor acting as a tumor vascular ...
Manufactured by:ORYX GmbH & Co. KG based inBaldham, GERMANY
Several cancers arise from the lack of DNA mismatch repair (MMR) resulting in the accumulation of thousands of single deletions or insertions at coding microsatellites (MSI-H). These mutations lead to the inactivation of specific proteins and to the expression of frameshift peptides (FSPs). These FSPs are tumor-specific antigens, which are constantly expressed. Cancers with MSI-H mutations ...
Manufactured by:Kyoto Kagaku Co., Ltd. based inKyoto, JAPAN
A new abdominal phantom to conduct studies and training of fusion imaging for wide range of clinical applications. (CT & ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
Glycosylation is a post-translational modification that occurs inside the cell and results in the addition of sugar motifs, “glycans”, to proteins and lipids that are, in most cases, destined for the cell surface. These glycan structures form the “glycome” and play an integral role in cell-to-cell and cell-to-matrix interactions through modulation of adhesion and cell ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...
Manufactured by:ORYX GmbH & Co. KG based inBaldham, GERMANY
ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. ParvOryx (parvus = ...